Erythema multiforme caused by triple therapy with amoxicillin, clarithromycin and vonoprazan for Helicobacter pylori.
Department of Dermatology, Toyokawa City Hospital, Toyokawa, Japan.|Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Koji
K
Kamiya
Department of Dermatology, Toyokawa City Hospital, Toyokawa, Japan.
Eiichi
E
Nishio
Department of Dermatology, Toyokawa City Hospital, Toyokawa, Japan.
Ai
A
Horio
Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Yoshiki
Y
Tokura
D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage / Q000009:adverse effects*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects; D017291:Clarithromycin / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D004892:Erythema Multiforme / Q000139:chemically induced* / Q000473:pathology; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects*; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*
C552956:1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine; D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors; D011758:Pyrroles; D013449:Sulfonamides; D000658:Amoxicillin; D017291:Clarithromycin